SeaStar Medical is a commercial-stage device company whose entire equity value now sits between a working pediatric product and an adult trial the balance sheet cannot finish on cash alone. The company sells QUELIMMUNE, an approved Selective Cytopheretic Device for children with sepsis-related acute kidney injury who already sit on renal replacement therapy, and that product is no longer a science project. Net product sales reached $1.1 million in the first half, and the customer list at twenty children's hospitals has doubled since the start of the year. The same device, in a larger cartridge, is the subject of NEUTRALIZE-AKI, a three-hundred-thirty-nine-patient adult pivotal study whose composite endpoint is ninety-day death or dialysis dependence. The market is not debating whether the pediatric line exists. The market is debating whether that line is a proof of mechanism that carries into adults, or a humanitarian franchise that never funds the study that would make the stock a franchise.
The cash math is the binding constraint, not the science. Cash at mid-year was $7.0 million, down from $12.0 million at year-end. First-half operating cash use was $5.8 million. Management states existing cash does not cover operations, including trial costs, for twelve months from issuance of the latest quarterly statements, and that this raises substantial doubt about continuation as a going concern. Pediatric gross margin held at 91 percent, which is the economic argument bulls use to claim the model scales. That margin sits on $54 thousand of cost of goods. Quarterly sales were $615 thousand against a much larger expense base. The pediatric line is a high-margin beachhead. It is not a self-funding engine for a multi-year adult premarket approval campaign.
Three named events in the last several months change the operating setup without solving the cash problem. First, the Food and Drug Administration cut the mandatory SAVE post-approval registry after early commercial safety data showed no device-related adverse events, and the company enrolled the fiftieth patient in early March. That cut removes a multi-year institutional-review tax that had slowed hospital activation. Second, federal inpatient procedure codes assigned in June take effect on the first of October and give hospitals a standardized way to bill the therapy. Third, Nasdaq lifted the Mandatory Panel Monitor on the first of July after stockholders' equity stayed above the listing floor. None of those events puts twelve months of cash on the balance sheet.
The shares last printed near $3.03 with a market value of about $13 million. Cash was roughly $7 million and funded debt is almost nil. That is a small option premium on an adult indication management describes as fifty times the pediatric opportunity. The bear case is already on the page: another reverse split sits in recent history, the Lincoln Park standby line and the Wainwright at-the-market facility are the only standing sources of cash, and both convert scarcity into dilution at a discount to the tape. The bull case is that a clean adult composite endpoint plus a modular premarket path re-rates a tiny equity into a platform device company. The open question is which arrives first, the trial readout or the next distressed raise.